PF-04929113

N/A

Report date: 2022/08/12 15:56:50
NME

Base Information

Drug NamePF-04929113
Drug Alias NamePF-4929113SNX-5422PF-04929113PF-113
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHeat shock protein HSP90 inhibitors
TargetsHeat shock protein HSP90
Therapy Area/IndicationsHematologic NeoplasmsLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer IncEsanex IncSerenex Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSerenex IncPfizer IncEsanex Inc +[4] 
Active IndicationsN/A
Inactive IndicationsHematologic NeoplasmsLymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A